Published in Nat Biotechnol on February 22, 2009
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol (2009) 3.55
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci U S A (2011) 2.68
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
A transposon and transposase system for human application. Mol Ther (2010) 2.28
High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat Rev Cancer (2009) 2.06
Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet (2011) 2.02
A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res (2009) 1.86
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet (2013) 1.60
Towards better mouse models: enhanced genotypes, systemic phenotyping and envirotype modelling. Nat Rev Genet (2009) 1.59
Mobile element scanning (ME-Scan) by targeted high-throughput sequencing. BMC Genomics (2010) 1.54
Whole genome resequencing reveals natural target site preferences of transposable elements in Drosophila melanogaster. PLoS One (2012) 1.40
Novel molecular and computational methods improve the accuracy of insertion site analysis in Sleeping Beauty-induced tumors. PLoS One (2011) 1.38
Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet (2012) 1.38
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res (2009) 1.34
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer (2012) 1.32
A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet (2015) 1.23
Genetically engineered mouse models in cancer research. Adv Cancer Res (2010) 1.18
Sleeping beauty transposition from nonintegrating lentivirus. Mol Ther (2009) 1.18
Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis. PLoS Genet (2013) 1.15
Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther (2014) 1.13
A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci U S A (2012) 1.12
High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. Genome Res (2011) 1.12
A Sleeping Beauty transposon-mediated screen identifies murine susceptibility genes for adenomatous polyposis coli (Apc)-dependent intestinal tumorigenesis. Proc Natl Acad Sci U S A (2011) 1.09
Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods (2013) 1.08
The expanding universe of transposon technologies for gene and cell engineering. Mob DNA (2010) 1.08
The mouse genetics toolkit: revealing function and mechanism. Genome Biol (2011) 1.05
Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet (2013) 1.04
Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res (2013) 1.01
TAPDANCE: an automated tool to identify and annotate transposon insertion CISs and associations between CISs from next generation sequence data. BMC Bioinformatics (2012) 1.01
Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas. Cancer Res (2010) 0.98
Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther (2012) 0.98
Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst (2012) 0.98
New methods for finding common insertion sites and co-occurring common insertion sites in transposon- and virus-based genetic screens. Nucleic Acids Res (2012) 0.98
Unexpectedly high copy number of random integration but low frequency of persistent expression of the Sleeping Beauty transposase after trans delivery in primary human T cells. Hum Gene Ther (2010) 0.97
piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice. PLoS One (2011) 0.95
Modeling hepatitis B virus X-induced hepatocellular carcinoma in mice with the Sleeping Beauty transposon system. Hepatology (2011) 0.95
Sleeping Beauty mutagenesis in a mouse medulloblastoma model defines networks that discriminate between human molecular subgroups. Proc Natl Acad Sci U S A (2013) 0.95
PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. Cancer Res (2012) 0.94
Merlin in organ size control and tumorigenesis: Hippo versus EGFR? Genes Dev (2010) 0.94
Mobilizing diversity: transposable element insertions in genetic variation and disease. Mob DNA (2010) 0.93
Transposon-based screens for cancer gene discovery in mouse models. Semin Cancer Biol (2010) 0.93
Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer. Semin Cancer Biol (2011) 0.92
Cancer gene discovery: exploiting insertional mutagenesis. Mol Cancer Res (2013) 0.88
Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology (2012) 0.88
Remobilization of Tol2 transposons in Xenopus tropicalis. BMC Dev Biol (2010) 0.87
Efficient transposition of Tol2 in the mouse germline. Genetics (2009) 0.87
Somatic mutagenesis with a Sleeping Beauty transposon system leads to solid tumor formation in zebrafish. PLoS One (2011) 0.85
Identification of a neuronal transcription factor network involved in medulloblastoma development. Acta Neuropathol Commun (2013) 0.85
A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model. Blood (2013) 0.85
Modular assembly of transposon integratable multigene vectors using RecWay assembly. Nucleic Acids Res (2013) 0.84
Genetic screens using the piggyBac transposon. Methods (2010) 0.84
Controlled insertional mutagenesis using a LINE-1 (ORFeus) gene-trap mouse model. Proc Natl Acad Sci U S A (2013) 0.83
Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugase regulation by Tal1. J Biol Chem (2009) 0.83
Genetic signature of histiocytic sarcoma revealed by a sleeping beauty transposon genetic screen in mice. PLoS One (2014) 0.83
RNA sequencing of Sleeping Beauty transposon-induced tumors detects transposon-RNA fusions in forward genetic cancer screens. Genome Res (2015) 0.82
Why men are at higher risk for hepatocellular carcinoma? J Hepatol (2012) 0.82
Sleeping Beauty transposon insertional mutagenesis based mouse models for cancer gene discovery. Curr Opin Genet Dev (2015) 0.82
Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proc Natl Acad Sci U S A (2013) 0.82
Novel principles of gamma-retroviral insertional transcription activation in murine leukemia virus-induced end-stage tumors. Retrovirology (2014) 0.81
Cancer gene discovery in mouse and man. Biochim Biophys Acta (2009) 0.81
Sequencing methods and datasets to improve functional interpretation of sleeping beauty mutagenesis screens. BMC Genomics (2014) 0.81
Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. Cell Rep (2016) 0.80
Somatic genetics empowers the mouse for modeling and interrogating developmental and disease processes. PLoS Genet (2011) 0.79
Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies. Semin Cell Dev Biol (2014) 0.79
Effective gene trapping mediated by Sleeping Beauty transposon. PLoS One (2012) 0.79
Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions. In Vivo (2012) 0.78
Sleeping Beauty transposon system harboring HRAS, c-Myc and shp53 induces sarcomatoid carcinomas in mouse skin. Oncol Rep (2013) 0.78
Transposon-mediated mutagenesis of somatic cells in the mouse for cancer gene identification. Methods (2009) 0.78
Identification of Sleeping Beauty transposon insertions in solid tumors using linker-mediated PCR. J Vis Exp (2013) 0.76
Exploiting the power of LINE-1 retrotransposon mutagenesis for identification of genes involved in embryonic stem cell differentiation. Stem Cell Rev (2014) 0.76
Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers. Cancer Biol Ther (2015) 0.76
Hydrodynamic delivery of Cre protein to lineage-mark or time-stamp mouse hepatocytes in situ. PLoS One (2014) 0.76
The utility of transposon mutagenesis for cancer studies in the era of genome editing. Genome Biol (2015) 0.76
When sleeping beauty wakes up and jumps into a cancer-minded environment. Hepatology (2009) 0.75
Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors. Cancers (Basel) (2016) 0.75
PiggyBac transposon-based polyadenylation-signal trap for genome-wide mutagenesis in mice. Sci Rep (2016) 0.75
piggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in mice. Proc Natl Acad Sci U S A (2017) 0.75
Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification. Proc Natl Acad Sci U S A (2017) 0.75
Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma. World J Gastroenterol (2015) 0.75
Novel strategies for gene trapping and insertional mutagenesis mediated by Sleeping Beauty transposon. Mob Genet Elements (2013) 0.75
Jump-starting cancer gene discovery. Nat Biotechnol (2009) 0.75
Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget (2017) 0.75
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Hepatocellular carcinoma. Lancet (2003) 22.54
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem (1999) 10.14
Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell (1997) 8.68
Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc Natl Acad Sci U S A (1997) 8.35
Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature (2005) 6.40
Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature (2005) 6.20
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature (1991) 6.04
Gene disruptions using P transposable elements: an integral component of the Drosophila genome project. Proc Natl Acad Sci U S A (1995) 5.76
P-element-mediated enhancer detection: a versatile method to study development in Drosophila. Genes Dev (1989) 5.76
A purified mariner transposase is sufficient to mediate transposition in vitro. EMBO J (1996) 5.34
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res (2000) 4.79
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
Transposition and gene disruption in the male germline of the mouse. Genesis (2001) 2.98
Region-specific saturation germline mutagenesis in mice using the Sleeping Beauty transposon system. Nat Methods (2005) 2.70
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
Efficient chromosomal transposition of a Tc1/mariner- like transposon Sleeping Beauty in mice. Proc Natl Acad Sci U S A (2001) 2.51
Transposase is the only nematode protein required for in vitro transposition of Tc1. Genes Dev (1996) 2.48
The mechanism of transposition of Tc3 in C. elegans. Cell (1994) 2.37
Genetics of hepatocellular carcinoma. Semin Cancer Biol (2000) 2.30
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A (2002) 2.24
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA (2008) 1.94
Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat Protoc (2007) 1.73
Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis. Br J Cancer (2005) 1.64
Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene (2003) 1.52
Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res (2007) 1.43
Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol (2008) 1.41
Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther (2006) 1.32
A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains. Structure (2004) 1.24
Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res (2001) 1.22
Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I. Mol Ther (2007) 1.21
Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat (2002) 1.21
MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res (2004) 1.21
Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp Cell Res (2003) 1.19
The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat (1994) 1.17
Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer (2007) 1.13
In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol (2007) 1.11
A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer (2006) 1.10
A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver. Hepatology (2008) 1.09
Redox-sensitive transactivation of epidermal growth factor receptor by tumor necrosis factor confers the NF-kappa B activation. J Biol Chem (2001) 1.07
Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. Clin Cancer Res (2006) 1.02
Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis. Oncogene (2003) 0.97
EGFR and gastrointestinal stromal tumor: an immunohistochemical and FISH study of 82 cases. Mod Pathol (2007) 0.89
Chromosomal aberrations in hepatocellular carcinomas: relationship with pathological features. Hepatology (1997) 0.88
A minor tyrosine phosphorylation site located within the CAIN domain plays a critical role in regulating tissue-specific transformation by erbB kinase. J Virol (1995) 0.88
Involvement of ErbB2 in the signaling pathway leading to cell cycle progression from a truncated epidermal growth factor receptor lacking the C-terminal autophosphorylation sites. J Biol Chem (1996) 0.84
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Hepatocellular carcinoma. Lancet (2012) 18.09
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res (2003) 12.94
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res (2005) 11.23
Genomic instability in mice lacking histone H2AX. Science (2002) 10.23
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet (2005) 8.99
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell (2012) 6.49
Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature (2005) 6.40
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature (2005) 6.20
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature (2009) 5.90
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell (2006) 5.88
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J (2003) 5.61
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res (2012) 5.50
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
The Medicago genome provides insight into the evolution of rhizobial symbioses. Nature (2011) 4.94
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell (2006) 4.74
Identification of Vangl2 and Scrb1 as planar polarity genes in mammals. Nature (2003) 4.56
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
The microcosmos of cancer. Nature (2012) 4.50
Control of apoptosis by p53. Oncogene (2003) 4.46
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res (2004) 4.41
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science (2009) 4.16
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
New genes involved in cancer identified by retroviral tagging. Nat Genet (2002) 4.14
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Identification of an organelle receptor for myosin-Va. Nat Cell Biol (2002) 4.06
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03